Pfizer Corporation

John L LaMattina

Christopher A Lipinski

Frederick J Walker

Brian Thomas O'Neill

Ernest S Hamanaka

Lawrence Alan Reiter

Paul D Weeks

Peter A McCarthy

George Chang

This invention relates to mutual prodrugs of amlodipine and atorvastatin and to pharmaceutical compositions thereof. This invention also relates to methods of treating angina pectoris, atherosclerosis, and hypertension and hyperlipidemia in a mammal using those prodrugs and compositions. This invention also relates to methods of managing cardiac risk in a mammal, including humans, presenting with symptoms of cardiac risk by administering those prodrugs and compositions.

Mutual prodrugs of amlodipine and atorvastatin

2-Guanidino-4-arylthiazole compounds of the formula ##STR1## a pharmaceutically acceptable cationic or acid addition salt thereof wherein

2-guanidino-4-arylthiazoles for treatment of peptic ulcers

A compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydrogen; R.sup.2 is (C.sub.1 -C.sub.15) alkyl, (C.sub.3 -C.sub.15)alkenyl, phenyl, substituted phenyl, (C.sub.7 -C.sub.20)-phenylalkyl, or substituted (C.sub.7 -C.sub.20)phenylalkyl wherein the substituents on the substituted phenyl and substituted phenylalkyl are independently one or two of fluoro, chloro, (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3 alkoxy, and trifluoromethyl; or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached form a pyrrolodinyl, substituted pyrrolidinyl, piperidyl or substituted piperidyl group, wherein the substituents on said substituted pyrrolidinyl and piperidyl groups are independently one of (C.sub.1 -C.sub.6)alkyl, phenyl, and (C.sub.7 -C.sub.9)phenylalkyl; and R.sup.3 is hydrogen, (C.sub.1 -C.sub.6)alkyl, phenyl, substituted phenyl, (C.sub.7 -C.sub.9)phenylalkyl, or substituted (C.sub.7 -C.sub.9)phenylalkyl, wherein the substituents on the substituted phenyl and substituted phenylalkyl are independently one or two of fluoro, chloro, (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, and trifluoromethyl. The compounds are useful in treating inflammation or other leukotriene mediated diseases, including plumonary, asthmatic, allergic, and gastrointestinal diseases.

2-amino-5-hydroxy-4-pyrimidones

2-Amino-4-substituted-5-(hydroxy or alkoxy)pyrimidines, which may be 6-substituted, and derivatives thereof are inhibitors of leukotriene synthesis and are therefore useful for the treatment of pulmonary, inflammatory, allergic and cardiovascular diseases. The compounds are also cytoprotective and therefore useful in the treatment of peptic ulcers.

Hydroxy and alkoxy pyrimidines

A method for the treatment of gastrointestinal disorders in a patient which comprises administering to the patient a gastric anti-secretory effective amount of a 2-amino-5-hydroxy-4-methylpyrimidine or a substituted amino derivative thereof, optionally in admixture with an additional gastric anti-secretory agent.

Method for treatment of gastrointestinal disorders

An improved antiinflammatory composition and method of treating inflammation which employs a combination of an antiinflammatory agent (e.g. indomethacin or an oxicam) with a histamine-H.sub.2 antagonist selected from the group consisting of 2-guanidino-4-(4-imidazolyl)thiazole, 2-guanidino-4-(2-methyl-4-imidazolyl )thiazole, 2-(N-benzyl-N'-guanidino)-4-(2-methyl-4-imidazolyl)thiazole, 2-(N-pentyl-N'-guanidino)-4-(2-methyl-4-imidazolyl)thiazole and 2-guanidino-4-[2-(hexylamino)-4-imidazolyl]thiazole.

Formulation of antiinflammatory drugs

A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

2-guanidino-4-heteroarylthiazoles

Novel 2-amino-5-hydroxy-4-methylpyrimidines and substituted amino derivatives thereof useful as inhibitors of leukotriene synthesis for the treatment of pulmonary, inflammatory and cardiovascular diseases, cancer and psoriasis. In addition these compounds are cytoprotective and therefore useful in the treatment of peptic ulcers. A process for the preparation of such active compounds by ring rearrangement of 2-amino-5-acetyloxazole, pharmaceutical compositions containing the novel active compounds and compositions containing these compounds in combination with other anti-inflammatory agents or gastric anti-secretory agents.

2-Amino-5-hydroxy-4-methylpyrimidine derivatives

2-Guanidino-4-heteroarylthiazoles

Haloacetyl imidazoles

p-Nitrophenyl 3-bromo-2,2-diethoxypropionate, useful in the synthesis of highly functionalized small molecules and heterocycles, including pyromeconic acid and 6-methylpyromeconic acid.

p-Nitrophenyl 3-bromo-2,2-diethoxy-propionate and synthetic utility

Heretofore unavailable 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles; a novel process therefor, also advantageous for the preparation of known antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles; intermediate compounds therefor; and a method for treatment of ulcers in mammals therewith.

Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and

A series of 2-substituted-4-(4-imidazolyl)pyridines and the pharmaceutically acceptable acid addition salts thereof as histamine H.sub.2 -receptor inhibitors for controlling gastric acidity.

Growing community of inventors

Ledyard, CT, United States of America

John L LaMattina